Pharma & Life Sciences

Patent: Acetyl Glucosamine Improves Cognition

Patent: Acetyl Glucosamine Improves Cognition

Blueroot Health Expands Voluntary Recall of Vital Nutrients Aller-C Dietary Supplement Due to Undeclared Egg, Hazelnut, and Soy

Blueroot Health is expanding its voluntary recall of Vital Nutrients Aller-C dietary supplements to include all product from lot 25E04. The recall affects approximately 100 and 200 capsule bottles with lot numbers 25E04, 25E04-A, and 25E04-B, expiration date 05/27. The products were distributed nationwide from September 2025 through March 2026 and may contain undeclared egg, hazelnut, and soy allergens, posing a risk of serious or life-threatening allergic reactions.

Collagen Production Dietary Supplement Study

ClinicalTrials.gov has registered study NCT07521423, a clinical trial examining collagen production through dietary supplementation. The study focuses on understanding the effects of dietary supplements on collagen synthesis. Registration on ClinicalTrials.gov is required for certain clinical trials under federal law.

C-3002 Cervical Cancer Screening at CASCADE Sites, UNC Lineberger

NLM registered clinical trial NCT07520188 titled C-3002, a cervical cancer screening study conducted at CASCADE sites by UNC Lineberger. The registration provides trial identification, sponsor information, and study status for public transparency.

BXOS110 Injection Phase III Acute Ischaemic Stroke Trial

The National Library of Medicine registered a Phase III clinical trial (NCT07520565) evaluating BXOS110 Injection for acute ischaemic stroke. The trial appears to be investigating a novel therapeutic intervention. ClinicalTrials.gov serves as the public registry for clinical trials required under FDA regulations.

OCUL101 Neovascular AMD Phase II/III Trial

ClinicalTrials.gov registered Outlook Therapeutics' Phase II/III trial (NCT07520318) evaluating OCUL101 ophthalmic solution in treatment-naive subjects with neovascular age-related macular degeneration. The study will assess multiple endpoints including change from baseline in best-corrected visual acuity at 12 months.

MK-1045 Non-Hodgkin Lymphoma Phase 2 Trial, Merck

Merck registered a Phase 2 clinical trial (NCT07519772) evaluating MK-1045 for Non-Hodgkin Lymphoma on ClinicalTrials.gov. The trial is listed as a globally registered (GP) study. Clinical trial registration is required under FDAAA 801 for applicable trials and supports transparency in clinical research.

Bioequivalence Study Chiglitazar Metformin T2DM

The National Library of Medicine registered a new bioequivalence clinical trial on ClinicalTrials.gov. The study (NCT07519265) evaluates the bioequivalence of Chiglitazar and Metformin co-administration in patients with Type 2 Diabetes Mellitus (T2DM). The trial is listed as recruiting with an estimated enrollment of 36 participants at a single site in China.

HH-006 Chronic Hepatitis B Trial, Huahui Health

ClinicalTrials.gov registered the HH-006 clinical trial sponsored by Huahui Health, evaluating the safety and efficacy of an investigational treatment for chronic hepatitis B infection. The trial is now publicly listed with identifier NCT07519330, providing transparency on ongoing clinical research.

CAR 70-BCMA CAR-T Cells Relapsed Refractory Plasma Cell Neoplasms

ClinicalTrials.gov registered a new Phase 1/Phase 2 interventional study evaluating CAR 70-BCMA CAR-T cell therapy for adult patients with relapsed or refractory plasma cell neoplasms including multiple myeloma. The single-arm study will assess safety, tolerability, and efficacy of the BCMA-targeted autologous T-cell product. No compliance obligations are created by this registry entry.